| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00871039 Details | 2016-03-01 Interventional | 4 | 0 | Midazolam Propofol Alcoholism Respiration, Ar… | Due to logistical purposes - | |||
| NCT02362321 Details | 2016-02-29 Interventional | 4 | 20 | Dexamethasone Hematoma Hematoma, Subdu… Hematoma, Subdu… | Due to serious adverse events - | |||
| NCT00522301 Details | 2016-02-29 Interventional | 2 | 6 | Sorafenib Carcinoma, Ovar… Fallopian Tube … Fallopian Tube … Ovarian Cancer Primary Periton… | - Early termination as it would not meet it's primary endpoint of improved survival. None of the patients completed the study. | |||
| NCT00823095 Details | 2016-02-26 Interventional | 2 | 7 | Nitric Oxide Leg Ulcer Ulcer Chronic Ulcer o… | Subject recuitment halted and won't resume; subjects are no longer being treated. No data available for this study due to dissolution of company contracted to perform study analysis. | |||
| NCT00781482 Details | 2016-02-26 Interventional | 4 | 0 | Eszopiclone Zolpidem Healthy | Sponsor elected not to conduct study at this time. - | |||
| NCT00140790 Details | 2016-02-26 Interventional | 4 | 1000 | Valsartan Renal Insuffici… Hypertension | The number of actual events was extremely low. We extended the study period, but it was still
not enough. Also, many patients were loss of follow up. - | |||
| NCT00370149 Details | 2016-02-24 Interventional | 4 | [1 Refs] | 326 | Anti-Bacterial … Infections Infection Preve… | Blinded interim analysis resulted in early termination of the study. A blinded interim analysis by an independent Data Safety Monitoring Board resulted in early termination of the study: of 288 evaluable patients, the rates of CRBSI and line-related complications were similar between the 2 groups. | ||
| NCT01093846 2009-013901-33 Details | 2016-02-22 Interventional | 3 | 59 | Antibodies, Mon… Uveitis | Core Study in Behcet's disease with mostly active uveitis did not meet its primary endpoint Due to early termination of the study AIN457C2303E1, the analysis of extension period was changed. No efficacy analyses were completed, the safety analyses were reduced to summary of AEs occurred during the extension and safety follow-up periods. | |||
| NCT00115063 Details | 2016-02-22 Interventional | 4 | 390 | Diethylpropion Orlistat Sibutramine Obesity | ethical issues of continuing control group without treatment The study was stopped prematurely for efforts to be focused on assisting the Office of Group Benefits (OGB) in translating a policy that would allow for physician certification in order to offer participants the intensive treatment. | |||
| NCT00582400 Details | 2016-02-19 Interventional | 2 | 9 | Arsenic Trioxid… Carcinoma Carcinoma, Hepa… | recruiting or enrolling participants has halted prematurely and will not resume; participants
are no longer being examined or treated - | |||
| NCT00483119 Details | 2016-02-18 Interventional | 2 | 9 | Antibodies Cyclophosphamid… Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Pemphigus Pemphigus Vulga… | Study was terminated due to the death of the PI. Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed. | |||
| NCT02411877 Details | 2016-02-17 Interventional | 2 | 0 | Clotrimazole Miconazole Hypothermia Ischemia Ischemic Stroke | It was decided that it was not feasible to continue this study. - | |||
| NCT01497626 Details | 2016-02-17 Interventional | 1 | 15 | Bortezomib Lapatinib Neoplasms Advanced Solid … | Drug support withdrawn - | |||
| NCT00850161 Details | 2016-02-15 Interventional | 2 | 0 | Insulin Insulin Aspart Insulin, Globin… Diabetes Mellit… Type 1 Diabetes… | Business purposes. - | |||
| NCT00793468 Details | 2016-02-15 Interventional | 2 | 0 | Nicotine Substance-Relat… Substance Depen… | Study halted prior to enrollment of patients - | |||
| NCT00130936 Details | 2016-02-15 Interventional | 1/2 | - | Capecitabine Carboplatin Epirubicin Esophageal Canc… Gastric Cancer Tumors | - - | |||
| NCT02537561 Details | 2016-02-11 Interventional | 1 | 0 | Cisplatin Gemcitabine Talazoparib Carcinoma Carcinoma, Non-… Lung Neoplasms Carcinoma, Non-… Non-Small Cell … Non-Small-Cell … Nonsmall Cell L… Solid Tumors | The pharmaceutical company did not want to follow through with support for the study. - | |||
| NCT01200342 Details | 2016-02-11 Interventional | 2 | 7 | Carboplatin Oblimersen Paclitaxel Melanoma | Pharmaceutical company no longer manufacturing investigational product. - | |||
| NCT01888042 Details | 2016-02-10 Interventional | 2 | 61 | Everolimus Carcinoma, Rena… Kidney Neoplasm… Kidney Cancer | - - | |||
| NCT01534455 2010-023237-37 Details | 2016-02-10 Interventional | 2 | 43 | Lapatinib Breast Neoplasm… Metastatic Brea… | very slow patient recruitment and concerns about the actuality of the study design - |